Drug Combination Helps Patients with Advanced Lung Cancer
July 23rd, 2009
A study examining erlotinib-bevacizumab combination therapy in patients with advanced non-small cell lung cancer (NSCLC) suggests that disease progression can be delayed with this therapy.
These findings were presented by Vincent Miller, MD at the 2009 Annual Meeting of the American Society of Clinical Oncology.